In the shadow of the fastest-growing Ebola outbreak in recorded history, the Democratic Republic of Congo has begun vaccinating fifty thousand frontline health workers in Ituri and North Kivu provinces with a tool designed for a different enemy. The Ervebo vaccine, developed against the Zaire strain, is being deployed under compassionate-use authorization against the Bundibugyo variant — a strain it was never built to fight — because no alternative exists. With 3,639 lives already lost since May, this campaign is less a solution than a covenant between necessity and hope: a carefully monitored
DRC deploys Ebola vaccine for health workers amid record outbreak
The Ebola outbreak has killed at least 3,639 people and infected 7,541 since May, with health workers facing particular exposure and risk.
We don't know to what degree it might be effective
Mark
Why use a vaccine that wasn't designed for this strain? Why not wait for one that was?
Mimi
Because people are dying now. There is no licensed vaccine for Bundibugyo. Clinical trials for a proper one are ongoing, but that takes time—months, maybe longer. Health workers can't wait.
Luke
But we should be clear: the WHO is saying animal trials suggest some protection. That's not the same as knowing it works in humans against this strain. The twenty thousand in the trial will help answer that question.
Mark
What happens to the other thirty thousand who aren't in the trial?
Mimi
They get the vaccine too, but their outcomes won't be systematically tracked the same way. It's still a compassionate-use situation—emergency deployment under special rules.
Luke
Right. So we'll have data on twenty thousand, but not on the full fifty thousand. That's an important limitation.
Mark
Are health workers actually willing to take it?
Mimi
They don't really have a choice, according to one doctor in Bunia. It's being presented as mandatory for frontline staff. Some had already received it before.
Luke
That's worth noting—there's a difference between voluntary uptake and mandatory deployment. The doctor's language suggests this is being required, not offered.
Mark
What do the organizations running this think is actually happening with the outbreak?
Mimi
The WHO sees signs transmission might be slowing. But Doctors Without Borders said explicitly on Friday that there's no clear evidence the epidemic is under control.
Luke
That's a significant disagreement between two major players. The reader should know that the outbreak is still growing in at least one province—North Kivu—and the death toll keeps rising. The vaccine is a tool, but it's not a solution yet.
Il Polso
- The outbreak has killed 3,639 people and infected 7,541 since May, with cases still climbing sharply in North Kivu — making this the deadliest and fastest-spreading Ebola event on record.
- Health workers are at the center of the crisis, moving between patients and clinics at the highest risk, yet the only available vaccine was engineered for a strain different from the one now killing their colleagues.
- Twenty thousand of the fifty thousand recipients have been enrolled in a one-year clinical trial, turning an emergency vaccination drive into a live experiment — because there is simply no proven alternative to monitor.
- WHO officials point to early animal-trial data and 'encouraging signs' of slowing transmission, while MSF warns there is no clear evidence the epidemic is under control and cases continue to rise.
- Health workers like Dr. Jeannot Elua are accepting the vaccine not out of confidence but out of the absence of choice — a quiet, telling measure of how desperate the situation remains.
In the shadow of the fastest-growing Ebola outbreak in recorded history, the Democratic Republic of Congo has begun vaccinating fifty thousand frontline health workers in Ituri and North Kivu provinces with a tool designed for a different enemy. The Ervebo vaccine, developed against the Zaire strain, is being deployed under compassionate-use authorization against the Bundibugyo variant — a strain it was never built to fight — because no alternative exists. With 3,639 lives already lost since May, this campaign is less a solution than a covenant between necessity and hope: a carefully monitored act of collective courage in the face of profound uncertainty.
On a Saturday morning in Bunia, in northeastern Congo's Ituri province, health workers began lining up for doses of Ervebo — a vaccine developed for a different strain of Ebola than the one now tearing through their communities. The campaign targets fifty thousand frontline workers across Ituri and North Kivu, the twin epicenters of the fastest-growing Ebola outbreak in recorded history. No licensed vaccine exists for the Bundibugyo variant. No proven treatment exists either. What is unfolding is, by design and necessity, a monitored experiment.
The human toll has been staggering: at least 3,639 dead and 7,541 infected since May, with North Kivu seeing sharp increases in recent weeks. Provincial Governor Major-General Gaby Kasongo Mulumba acknowledged what those inside the health system already understand — that the workers receiving these injections are the most exposed people in the response, moving constantly between patients, clinics, and communities.
Twenty thousand of the vaccinated workers have enrolled in a one-year clinical trial to measure whether Ervebo offers any real protection against Bundibugyo. The WHO approved seventy thousand doses for distribution under a compassionate-use framework — a legal pathway that permits deployment in serious disease situations even without formal approval for that specific strain. Early animal-trial data offers a thread of hope, but officials have been candid about the limits of what is known.
Dr. Jeannot Elua, working at a Bunia health facility, called the vaccine beneficial — then added that health workers 'don't really have a choice.' That phrase captures the moral and medical reality of the moment. The WHO has cited encouraging signs that transmission may be slowing. MSF has countered that there is no clear evidence the epidemic is under control. The vaccine is a tool, not an answer, and everyone involved understands the difference.
The vaccine campaign began on a Saturday morning in Bunia, a city in northeastern Congo's Ituri province, where the fastest-growing Ebola outbreak in recorded history is unfolding. Health workers lined up to receive doses of Ervebo, a vaccine developed years ago for a different strain of the virus—one that offers no guarantee of protection against the Bundibugyo variant now spreading through their communities.
Fifty thousand frontline workers across Ituri and North Kivu provinces will receive the injection as part of an emergency response backed by the World Health Organization and Doctors Without Borders. Among them, twenty thousand have enrolled in a one-year clinical trial designed to measure whether the vaccine offers any real protection against the current outbreak. No licensed vaccine exists for Bundibugyo. No proven treatment exists either. This campaign is, in essence, a carefully monitored experiment born of necessity.
The outbreak has already killed at least 3,639 people and infected 7,541 since May, according to local health authorities. Another 1,823 have recovered. The numbers keep climbing, particularly in North Kivu, where cases have been rising sharply in recent weeks. Provincial Governor Major-General Gaby Kasongo Mulumba acknowledged what everyone in the health system already knows: the workers receiving these vaccines are "particularly exposed and deeply involved in the response." They move between patients, between clinics, between communities. They carry the highest risk.
Steve Ahuka, a Congolese official on the health task force coordinating the outbreak response, was candid about the uncertainty. "We don't know to what degree it might be effective against the Bundibugyo strain," he said. The WHO has pointed to early data from animal trials suggesting some protection may be possible, but animal trials are not human bodies, and hope is not certainty. The vaccine is being deployed under what regulators call a compassionate-use programme—a legal framework that permits medical products to be used in serious disease situations even when they have not been formally approved for that specific use. The WHO approved seventy thousand doses for distribution in Congo in August.
Dr. Jeannot Elua, working at a health facility in Bunia, called the vaccine "beneficial" when speaking to reporters. But his next words carried the weight of constraint: "We healthcare workers don't really have a choice. We are going to receive it." Some of his colleagues had already received Ervebo during an earlier outbreak response. Elua himself had taken it before, when it was mandatory. Now they were being asked to trust it again, this time against an enemy it was never designed to fight.
The optimism and caution in the response reflect a widening gap in how the outbreak is being assessed. WHO experts have cited "encouraging signs" that transmission may be slowing. But Doctors Without Borders issued a warning on Friday: there is no clear evidence the epidemic is coming under control. Cases continue to rise. Health workers continue to fall ill. The vaccine offers a tool, but not an answer—and everyone involved knows it.
Citazioni salienti
We don't know to what degree it might be effective against the Bundibugyo strain— Steve Ahuka, Congolese health task force official
We healthcare workers don't really have a choice. We are going to receive it.— Dr. Jeannot Elua, health worker in Bunia
Vuoi la storia completa?
Leggi l'originale su Al Jazeera ↗
Health & Medicine